



**Supplementary Figure 1. Deletion of *Ptpn21* promotes development and progression of *MLL-AF9*-induced leukemia.** Lin<sup>-</sup> cells isolated from *Ptpn21*<sup>-/-</sup> and *Ptpn21*<sup>+/+</sup> mice were infected with *MSCV-MLL-AF9-IRES-GFP* retrovirus. Entire cell populations ( $5 \times 10^5$  cells/mouse) were transplanted into sublethally irradiated (700 rad with a cesium irradiator) BoyJ mice for *in vivo* expansion of leukemic cells. GFP<sup>+</sup> leukemic cells sorted from the recipient mice were transplanted into sublethally irradiated BoyJ mice. Twenty-five days after leukemic cell inoculation, recipient mice (n=5 mice per group) were sacrificed. Spleens were weighted (A), white blood cell counts in the peripheral blood were determined by a hematology analyzer (B), and leukemic cells (GFP<sup>+</sup>) in the peripheral blood, BM, and spleen were assessed by FACS analyses (C). Data shown are mean  $\pm$  standard deviation of all mice examined. \*\*\*  $P < .001$ .



**Supplementary Figure 2. Enhanced growth of *MLL-AF9-Ptpn21<sup>-/-</sup>* leukemic cells *in vivo*.** (A) Lin<sup>-</sup> cells isolated from *Ptpn21<sup>-/-</sup>* and *Ptpn21<sup>+/+</sup>* mice were infected with *MSCV-MLL-AF9-IRES-GFP* retrovirus. GFP<sup>+</sup> *MLL-AF9*-transduced cells were sorted by FACS. 1x10<sup>6</sup> GFP<sup>+</sup> leukemia cells were transplanted into lethally irradiated (900 rad with an X-ray irradiator) BoyJ mice (n=6 mice per group). Seventeen hours after transplantation, BM cells were harvested and the frequency of homed GFP<sup>+</sup> leukemia cells were measured by FACS. (B-D) Lin<sup>-</sup> cells isolated from *Ptpn21<sup>-/-</sup>* and *Ptpn21<sup>+/+</sup>* mice were infected with *MSCV-MLL-AF9-IRES-GFP* retrovirus. GFP<sup>+</sup> *MLL-AF9*-transduced cells were sorted by FACS. 6.6x10<sup>4</sup> GFP<sup>+</sup> leukemia cells were transplanted into lethally irradiated BoyJ mice (n=6 mice per group). Seventeen days after leukemic cell inoculation, recipient mice (n=3 to 4 mice per group) were sacrificed. White blood cell counts in the peripheral blood were determined by a hematology analyzer (B). GFP<sup>+</sup> leukemic cells in the peripheral blood, BM, and spleen (C) were assessed by FACS analyses. Cell cycle distribution of GFP<sup>+</sup> leukemic cells in the BM were determined by multi-color FACS analyses (n=3 mice per group) (D). Data shown are mean ± standard deviation of all mice examined. \* *P* < 0.05; \*\* *P* < 0.01.



**Supplementary Figure 3. Correlation of *PTPN21* expression levels with prognosis in AML patients.**

Data mining was performed to determine the correlation between the expression levels of *PTPN21* and the survival of AML patients in the TCGA database. Overall survival rates of AML patients with high and low *PTPN21* expression levels are shown (Left, 10% cut-off threshold; Right, 20% cut-off threshold). The Log-rank (Mantel-Cox) test was used to determine statistical significance.